Trial Profile
An Open-Label Study of Oral CEP-701 in Patients With Polycythaemia Vera or Essential Thrombocytosis With the JAK2 V617F Mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Lestaurtinib (Primary)
- Indications Polycythaemia vera; Thrombocytosis
- Focus Pharmacodynamics; Pharmacogenomic
- Sponsors Cephalon
- 15 Aug 2014 New trial record
- 23 Aug 2011
- 15 Jul 2009